ES2195638T3 - Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida. - Google Patents

Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.

Info

Publication number
ES2195638T3
ES2195638T3 ES99957320T ES99957320T ES2195638T3 ES 2195638 T3 ES2195638 T3 ES 2195638T3 ES 99957320 T ES99957320 T ES 99957320T ES 99957320 T ES99957320 T ES 99957320T ES 2195638 T3 ES2195638 T3 ES 2195638T3
Authority
ES
Spain
Prior art keywords
hydroclorotiazida
cardevilol
preparations
solid form
pharmaceutical combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99957320T
Other languages
English (en)
Inventor
Rudolf Heller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2195638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2195638T3 publication Critical patent/ES2195638T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparación de una combinación farmacéutica que contiene las substancias activas carvedilol o una sal farmacéuticamente aceptable de la misma e hidroclorotiazida o una sal farmacéuticamente aceptable de la misma, así como aditivos usuales farmacéuticamente.
ES99957320T 1998-11-27 1999-11-20 Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida. Expired - Lifetime ES2195638T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98122489 1998-11-27

Publications (1)

Publication Number Publication Date
ES2195638T3 true ES2195638T3 (es) 2003-12-01

Family

ID=8233041

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99957320T Expired - Lifetime ES2195638T3 (es) 1998-11-27 1999-11-20 Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.

Country Status (22)

Country Link
US (3) US6403579B1 (es)
EP (1) EP1131072B1 (es)
JP (2) JP2002531395A (es)
KR (1) KR100421347B1 (es)
CN (1) CN1184971C (es)
AR (1) AR020287A1 (es)
AT (1) ATE238056T1 (es)
AU (1) AU765977B2 (es)
BR (1) BR9915610A (es)
CA (1) CA2352361C (es)
CO (1) CO5011053A1 (es)
DE (1) DE69907252T2 (es)
DK (1) DK1131072T3 (es)
ES (1) ES2195638T3 (es)
MY (1) MY121831A (es)
PE (1) PE20001302A1 (es)
PT (1) PT1131072E (es)
TR (3) TR200101470T2 (es)
TW (1) TWI228414B (es)
UY (1) UY25821A1 (es)
WO (1) WO2000032174A2 (es)
ZA (1) ZA200104280B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IN191028B (es) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
BR0312102A (pt) 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
WO2005030201A1 (en) * 2003-09-26 2005-04-07 Shuyi Zhang Sustained release preparation containing hydrochlorothiazide
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
DK1691804T3 (da) * 2003-12-02 2007-07-16 Nicox Sa Nitrooxydderivater af carvedilol og andre beta-blokkere som antihypertensive lægemidler
CA2598762A1 (en) * 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
EP2029112B2 (en) * 2006-06-16 2014-02-19 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US20130121916A1 (en) * 2010-03-10 2013-05-16 Sergio Baroni Compositions for Colon Lavage and Methods of Making and Using Same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
UA37214C2 (uk) * 1991-01-30 2001-05-15 Дзе Веллкам Фаундейшн Лімітед Таблетки, що диспергуються у воді, та спосіб їх виготовлення
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2752162B1 (fr) * 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida

Also Published As

Publication number Publication date
WO2000032174A2 (en) 2000-06-08
AR020287A1 (es) 2002-05-02
CA2352361C (en) 2007-01-02
KR100421347B1 (ko) 2004-03-06
ZA200104280B (en) 2002-08-26
AU1506500A (en) 2000-06-19
CA2352361A1 (en) 2000-06-08
CN1184971C (zh) 2005-01-19
TR200101470T2 (tr) 2001-11-21
TR200200981T2 (tr) 2002-06-21
DK1131072T3 (da) 2003-08-11
JP2002531395A (ja) 2002-09-24
MY121831A (en) 2006-02-28
US20040087578A1 (en) 2004-05-06
WO2000032174A3 (en) 2000-11-16
TR200200982T2 (tr) 2002-06-21
TWI228414B (en) 2005-03-01
PE20001302A1 (es) 2000-11-30
EP1131072B1 (en) 2003-04-23
DE69907252D1 (de) 2003-05-28
ATE238056T1 (de) 2003-05-15
UY25821A1 (es) 2001-07-31
CN1328460A (zh) 2001-12-26
PT1131072E (pt) 2003-08-29
DE69907252T2 (de) 2004-01-29
EP1131072A2 (en) 2001-09-12
US20020052367A1 (en) 2002-05-02
CO5011053A1 (es) 2001-02-28
BR9915610A (pt) 2001-08-14
KR20010080578A (ko) 2001-08-22
US6403579B1 (en) 2002-06-11
JP2007077160A (ja) 2007-03-29
AU765977B2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
AR032293A1 (es) Estuche farmaceutico
AR022252A1 (es) Composicion de administracion oral.
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
TR200402579T4 (tr) Kristalin monohidrat, bunun imalat yöntemi ve bir ilaç maddesinin imalatında kullanımı
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
SE9803272D0 (sv) A drug for cell regeneration
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene